ProCE Banner Activity

ATLAS-2M, Wk 96 Results: Long-Acting Injectable Cabotegravir + Rilpivirine Every 8 Wks Is Noninferior to Every 4 Wks

Slideset Download
Conference Coverage
Long-acting cabotegravir plus rilpivirine injections every 2 months are noninferior to monthly injections at Week 96 in virologically suppressed patients with no prior virologic failure.

Released: March 11, 2021

Expiration: March 10, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare